Roche's Vabysmo nears third indication

Swiss pharma giant Roche (ROG: SIX) has announced positive top-line long-term results from the global Phase III BALATON and COMINO studies, evaluating extended treatment intervals with Vabysmo (faricimab) in macular edema due to branch and central retinal vein occlusion.

The bispecific antibody showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

“These are the first retinal vein occlusion (RVO) studies to show vision maintenance and anatomical improvements up to 72 weeks in both central and branch RVO,” said Levi Garraway, Roche’s chief medical officer and head of global product development.